Buy Takhzyro (lanadelumab) Online For Sale
DISEASE INDICATIONS: Hereditary angioedema (HAE)
MANUFACTURER: Shire Pharmaceuticals
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Takhzyro is the brand name for the medication with the active ingredient lanadelumab. It is a prescription drug used for the prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older.
Takhzyro is the brand name for the medication with the active ingredient lanadelumab. It is a prescription drug used for the prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. Hereditary angioedema is a rare genetic condition characterized by sudden and severe swelling in various parts of the body, including the limbs, face, intestinal tract, and airway. These attacks can be life-threatening if they affect the airway.
Here is a general description of Takhzyro (lanadelumab):
Active Ingredient: Lanadelumab
Indication: Takhzyro is primarily used for the prophylactic (preventive) treatment of hereditary angioedema (HAE) attacks in eligible patients.
Mechanism of Action: Lanadelumab is a monoclonal antibody that works by binding to and inhibiting the activity of plasma kallikrein, a protein involved in the production of bradykinin. Bradykinin is a key mediator in the inflammatory process that leads to HAE attacks. By reducing bradykinin levels, Takhzyro helps prevent these attacks.
Administration: Takhzyro is typically administered via subcutaneous (under the skin) injection. The frequency of injections and dosage may vary depending on individual patient needs and physician recommendations.
Dosage: The specific dosage and administration schedule will be determined by a healthcare provider based on the patient’s individual needs and response to treatment.
Efficacy: Clinical trials have shown that Takhzyro can significantly reduce the frequency and severity of HAE attacks in patients.
Common Side Effects: Common side effects may include pain, redness, or swelling at the injection site, as well as headache. It’s important to note that not everyone will experience these side effects, and they should be discussed with a healthcare provider.
Precautions: Takhzyro should not be used to treat acute HAE attacks. It is intended for prevention only. Patients should inform their healthcare provider of any other medications they are taking and any underlying medical conditions. Women who are pregnant or breastfeeding should also discuss the risks and benefits of Takhzyro with their healthcare provider.
As with any prescription medication, patients should follow their healthcare provider’s instructions regarding the use of Takhzyro. It is essential to have a thorough discussion with a healthcare professional about the medication’s benefits, potential side effects, and any other relevant information before starting this treatment.
300 mg solution for injection